SCHEMBL94772

SCHEMBL94772

[CH2]c1ccc(NC(=O)Oc2ccc(F)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.62
GAA P10253 4/20 0.51
KDM4E B2RXH2 4/20 0.51
MAPT P10636 3/20 0.51
THRB P10828 2/20 0.51
GFER P55789 2/20 0.51
TDP1 Q9NUW8 2/20 0.51
GLA P06280 1/20 0.51
BLM P54132 1/20 0.51
CASP6 P55212 1/20 0.51
ALDH1A1 P00352 6/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
CYP1A2 P05177 1/20 0.48
HPGD P15428 1/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
LMNA P02545 1/20 0.48
TP53 P04637 1/20 0.48
RAD51 Q06609 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL95221 0.83 GAA (0.51) FAAHGAAKDM4EMAPTTHRB
SCHEMBL14467690 0.83 GAA (0.73) FAAHGAAKDM4EMAPTTHRB
SCHEMBL10192034 0.83 FAAH (0.67) FAAHGAAKDM4EMAPTTHRB
SCHEMBL97442 0.83 GAA (0.51) GAAKDM4EMAPTTHRBGFER
SCHEMBL95577 0.83 ALDH1A1 (0.53) FAAHGAAKDM4EMAPTTHRB
SCHEMBL94538 0.83 SMN1; SMN2 (0.71) GAAKDM4EMAPTTHRBGFER
SCHEMBL95682 0.83 ALDH1A1 (0.70) FAAHGAAKDM4EMAPTTHRB
SCHEMBL1376459 0.83 ALDH1A1 (0.70) FAAHGAAKDM4EMAPTTHRB
Phenyl 4-Fluorophenylcarbamate SCHEMBL1892132 0.83 ALDH1A1 (0.70) FAAHGAAKDM4EMAPTTHRB
SCHEMBL28395058 0.83 ALDH1A1 (0.70) FAAHGAAKDM4EMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
CN-101068810-B Carbostyril compound OTSUKA PHARMA CO LTD 2011-02-09 CN disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
CN-101489555-A Nf-kappa OTSUKA PHARMA CO LTD (JP) 2009-07-22 CN disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
CN-101068810-A Carbostyril compound OTSUKA PHARMA CO LTD (JP) 2007-11-07 CN disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB FAAH 4020/4885GAA 4574/4885KDM4E 1125/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 FAAH 3506/4885GAA 4784/4885KDM4E 3919/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 FAAH 3506/4885GAA 4784/4885KDM4E 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.